دورية أكاديمية
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
| العنوان: | Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL) |
|---|---|
| المؤلفون: | Satoru Miura, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Yasushi Goto, MD, PhD, Hidetoshi Hayashi, MD, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Osamu Hataji, MD, PhD, Kohei Fujita, MD, PhD, Masahiro Seike, MD, PhD, Noriko Yanagitani, MD, PhD, Kazumi Nishino, MD, PhD, Satoshi Hara, MD, Ryota Saito, MD, PhD, Masahide Mori, MD, PhD, Takeshi Tsuda, MD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Tetsuya Mitsudomi, MD, PhD |
| المصدر: | JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100484- (2023) |
| بيانات النشر: | Elsevier, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Non–small cell lung cancer, Immune checkpoint inhibitors, Atezolizumab, Observational study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Introduction: The efficacy and safety of atezolizumab in previously treated patients with NSCLC have been established in the registrational phase 3 OAK trial. In this study, we evaluated the effectiveness and safety of atezolizumab monotherapy in a large real-world cohort to confirm the reproducibility of the results of the registrational trial. Methods: This was a multicenter, prospective, single-arm observational study. Consecutive patients with previously treated NSCLC scheduled to receive atezolizumab monotherapy were enrolled. The primary end point was the 18-month overall survival (OS) rate. The incidence of adverse events (AEs) and immune-related AEs was evaluated. Results: Overall, 1002 patients were included in the safety analysis set and 1000 in the full analysis set. Median follow-up was 11.5 months. Of the full analysis set, 62% were ineligible for the OAK trial (OAK-unlike subpopulation). The 18-month OS rate was 41.1%, with a median OS of 13.0 months (95% confidence interval: 12.2–15.1). The 18-month OS rate was 49.4% and 36.1% in OAK-like and OAK-unlike subpopulations, respectively; that in patients with Eastern Cooperative Oncology Group performance status greater than or equal to 2 was 14.3%. The incidence of AEs overall, in the OAK-like, and OAK-unlike subpopulations was 43.9%, 46.2%, and 42.5%; that of immune-related AEs was 19.0%, 20.1%, and 18.3%, respectively. Conclusions: The findings suggest that atezolizumab may be effective and safe for previously treated patients with NSCLC in real-world settings; however, atezolizumab administration should be considered carefully regarding the benefit–risk balance for the OAK-unlike subpopulation, especially in patients with Eastern Cooperative Oncology Group performance status greater than or equal to 2. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2666-3643 |
| العلاقة: | http://www.sciencedirect.com/science/article/pii/S2666364323000231Test; https://doaj.org/toc/2666-3643Test |
| DOI: | 10.1016/j.jtocrr.2023.100484 |
| الوصول الحر: | https://doaj.org/article/cf2603aadeec484c8f8d98e2ec1d639bTest |
| رقم الانضمام: | edsdoj.f2603aadeec484c8f8d98e2ec1d639b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.f2603aadeec484c8f8d98e2ec1d639b 983 3 Academic Journal academicJournal 983.050231933594 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.f2603aadeec484c8f8d98e2ec1d639b&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/cf2603aadeec484c8f8d98e2ec1d639b [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=26663643&ISBN=&volume=4&issue=3&date=20230301&spage=&pages=&title=JTO Clinical and Research Reports&atitle=Effectiveness%20and%20Safety%20of%20Atezolizumab%20Monotherapy%20in%20Previously%20Treated%20Japanese%20Patients%20With%20Unresectable%20Advanced%20or%20Recurrent%20NSCLC%3A%20A%20Multicenter%2C%20Prospective%2C%20Observational%20Study%20%28J-TAIL%29&id=DOI:10.1016/j.jtocrr.2023.100484 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Satoru+Miura%2C+MD%2C+PhD%22">Satoru Miura, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Makoto+Nishio%2C+MD%2C+PhD%22">Makoto Nishio, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Hiroaki+Akamatsu%2C+MD%2C+PhD%22">Hiroaki Akamatsu, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Yasushi+Goto%2C+MD%2C+PhD%22">Yasushi Goto, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Hidetoshi+Hayashi%2C+MD%2C+PhD%22">Hidetoshi Hayashi, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Akihiko+Gemma%2C+MD%2C+PhD%22">Akihiko Gemma, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Ichiro+Yoshino%2C+MD%2C+PhD%22">Ichiro Yoshino, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Toshihiro+Misumi%2C+PhD%22">Toshihiro Misumi, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Akito+Hata%2C+MD%22">Akito Hata, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Osamu+Hataji%2C+MD%2C+PhD%22">Osamu Hataji, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Kohei+Fujita%2C+MD%2C+PhD%22">Kohei Fujita, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Masahiro+Seike%2C+MD%2C+PhD%22">Masahiro Seike, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Noriko+Yanagitani%2C+MD%2C+PhD%22">Noriko Yanagitani, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Kazumi+Nishino%2C+MD%2C+PhD%22">Kazumi Nishino, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Satoshi+Hara%2C+MD%22">Satoshi Hara, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Ryota+Saito%2C+MD%2C+PhD%22">Ryota Saito, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Masahide+Mori%2C+MD%2C+PhD%22">Masahide Mori, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Takeshi+Tsuda%2C+MD%22">Takeshi Tsuda, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Shunichiro+Iwasawa%2C+MD%2C+PhD%22">Shunichiro Iwasawa, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Shintaro+Nakagawa%2C+MSc%22">Shintaro Nakagawa, MSc</searchLink><br /><searchLink fieldCode="AR" term="%22Tetsuya+Mitsudomi%2C+MD%2C+PhD%22">Tetsuya Mitsudomi, MD, PhD</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100484- (2023) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier, 2023. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Non–small+cell+lung+cancer%22">Non–small cell lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+checkpoint+inhibitors%22">Immune checkpoint inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Atezolizumab%22">Atezolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Observational+study%22">Observational study</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Introduction: The efficacy and safety of atezolizumab in previously treated patients with NSCLC have been established in the registrational phase 3 OAK trial. In this study, we evaluated the effectiveness and safety of atezolizumab monotherapy in a large real-world cohort to confirm the reproducibility of the results of the registrational trial. Methods: This was a multicenter, prospective, single-arm observational study. Consecutive patients with previously treated NSCLC scheduled to receive atezolizumab monotherapy were enrolled. The primary end point was the 18-month overall survival (OS) rate. The incidence of adverse events (AEs) and immune-related AEs was evaluated. Results: Overall, 1002 patients were included in the safety analysis set and 1000 in the full analysis set. Median follow-up was 11.5 months. Of the full analysis set, 62% were ineligible for the OAK trial (OAK-unlike subpopulation). The 18-month OS rate was 41.1%, with a median OS of 13.0 months (95% confidence interval: 12.2–15.1). The 18-month OS rate was 49.4% and 36.1% in OAK-like and OAK-unlike subpopulations, respectively; that in patients with Eastern Cooperative Oncology Group performance status greater than or equal to 2 was 14.3%. The incidence of AEs overall, in the OAK-like, and OAK-unlike subpopulations was 43.9%, 46.2%, and 42.5%; that of immune-related AEs was 19.0%, 20.1%, and 18.3%, respectively. Conclusions: The findings suggest that atezolizumab may be effective and safe for previously treated patients with NSCLC in real-world settings; however, atezolizumab administration should be considered carefully regarding the benefit–risk balance for the OAK-unlike subpopulation, especially in patients with Eastern Cooperative Oncology Group performance status greater than or equal to 2. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2666-3643 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://www.sciencedirect.com/science/article/pii/S2666364323000231; https://doaj.org/toc/2666-3643 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.jtocrr.2023.100484 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/cf2603aadeec484c8f8d98e2ec1d639b" linkWindow="_blank">https://doaj.org/article/cf2603aadeec484c8f8d98e2ec1d639b</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.f2603aadeec484c8f8d98e2ec1d639b ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.jtocrr.2023.100484
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Non–small cell lung cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => Immune checkpoint inhibitors
[Type] => general
)
[2] => Array
(
[SubjectFull] => Atezolizumab
[Type] => general
)
[3] => Array
(
[SubjectFull] => Observational study
[Type] => general
)
[4] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[5] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Satoru Miura, MD, PhD
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Makoto Nishio, MD, PhD
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hiroaki Akamatsu, MD, PhD
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yasushi Goto, MD, PhD
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hidetoshi Hayashi, MD, PhD
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Akihiko Gemma, MD, PhD
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ichiro Yoshino, MD, PhD
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Toshihiro Misumi, PhD
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Akito Hata, MD
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Osamu Hataji, MD, PhD
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kohei Fujita, MD, PhD
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Masahiro Seike, MD, PhD
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Noriko Yanagitani, MD, PhD
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kazumi Nishino, MD, PhD
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Satoshi Hara, MD
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ryota Saito, MD, PhD
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Masahide Mori, MD, PhD
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Takeshi Tsuda, MD
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shunichiro Iwasawa, MD, PhD
)
)
)
[19] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shintaro Nakagawa, MSc
)
)
)
[20] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tetsuya Mitsudomi, MD, PhD
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 03
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 26663643
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 4
)
[1] => Array
(
[Type] => issue
[Value] => 3
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => JTO Clinical and Research Reports
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |